Atea Pharmaceuticals Business Update Presentation at 7th Annual Evercore Conference
Atea Pharmaceuticals, Inc. is all set to present and provide a business update at the 7th Annual Evercore HealthCONx Conference on Wednesday, December 4, 2024, at 9:35 a.m. ET. The CEO and Founder, Jean-Pierre Sommadossi, PhD, along with other members of the Atea management team, will participate in a fireside chat.
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company that is deeply involved in the discovery and development of oral antiviral therapeutics to combat serious viral diseases. Their primary focus is on addressing the unmet medical needs of patients with severe viral infections.
Their research and development efforts are centered around leveraging their expertise in antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry, and virology. Atea has devised a proprietary nucleos(t)ide prodrug platform to create innovative product candidates to tackle single-stranded ribonucleic acid (ssRNA) viruses, which are known to cause serious viral diseases.
Their goal is to expand their pipeline of antiviral product candidates by combining their nucleos(t)ide platform with other types of antivirals that can complement their nucleos(t)ide products.
Currently, Atea is dedicated to developing a combination of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, to treat HCV. For more information about Atea Pharmaceuticals, you can visit their website at www.ateapharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The details shared are based on the Company’s current plans, expectations, and assumptions, but are subject to uncertainty. While the Company believes in the reasonableness of its expectations and beliefs, actual results may vary due to various factors. It’s essential to consider the risks and factors that could affect the actual results compared to the forward-looking statements provided.
